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1. INTRODUCTION 
Nature has evolved to create several essential 
compounds with high versatility, so that a few molecules 
can be used in a large variety of reactions. Initially, this 
represents an evolutionary advantage reducing the number 
of enzymes and compounds required for life. However, 
this same aspect imposes a serious drawback, since 
alterations affecting these few processes may lead to 
disease. Among these versatile compounds two have been 
shown of special relevance for the cell, ATP and S-
adenosylmethionine (SAM). This last metabolite was 
described for the first time in 1951 by Cantoni as an 
"active methionine" able to transmethylate in the absence 
of ATP (1). Although at that moment its exact nature was 
unknown, in this same paper the author indicated that 
SAM was a product of the reaction between ATP and 
methionine. Finally, in 1953 this researcher described the 
reaction catalyzed by the "methionine activating enzyme" 
and the chemical nature of SAM (2). 
The number and variety of biological processes that 
involve the use of SAM has increased along the years, so 
that nowadays the catalogue of reactions using this 
metabolite is as large as that of the processes utilizing ATP 
(3). This versatility of SAM relies in its chemical structure, 
which contains a quiral sulfonium group through which 
carbon-sulfur bonds with aminopropyl, methyl and 
adenosine groups are established. These groups are 
donated to a large variety of substrates upon nucleophilic 
attack of the corresponding carbon-sulfur bond (reviewed 
in (4,5)). Additionally, SAM can also transfer the rybosyl 
or amino groups in processes that have been described in 
bacteria or plants (3,6,7).  
Methyltransferases consume the majority of the SAM 
produced in any organism in reactions leading to the 
synthesis of small molecules (i.e. neurotransmitters, 
phosphatidylcholine, etc.), the modification of proteins 
(i.e. histones) and DNA, among others. The remaining 
SAM is involved in the synthesis of 5'-halogenated 
derivatives in marine organisms (adenosine group), 
queuosine (rybosyl group) and other hypermodified 
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nucleosides (3-amino carboxypropyl group), pelargonic 
acid (amino group), polyamines, molecules involved in 
bacterial signaling and ethylene (aminopropyl group). 
SAM can also be used both as cofactor or substrate by 
SAM radical proteins, which catalyze probably the last set 
of reactions involving this compound that has been 
identified to date (3,8). In mammals, transmethylations 
consume approximately 95% of the SAM produced and 
the rest is used for SAM decarboxylation, being 
decarboxylated SAM the genuine aminopropyl donor for 
the synthesis of the polyamines spermidine and spermine 
(4,9).  
2. THE METHIONINE CYCLE IN MAMMALS 
SAM synthesis is carried out by methionine 
adenosyltransferases (MATs; EC 2.5.1.6), also known as 
SAM synthetases, this step being the first and rate limiting 
of the methionine cycle (4) (Figure 1). Most of the 
information regarding this pathway has been obtained in 
liver, where a human adult processes up to 48% of the 
ingested methionine (9-11), but slowly information 
concerning other organs is becoming available (i.e. the 
cochlea (12)). The need for increasing the existing 
knowledge in extrahepatic tissues has been emphasized 
when impairments of the methionine cycle, and especially 
reductions in SAM concentrations or 
hyperhomocysteinemia, have been associated with 
different pathologies. Most of the diseases in which 
alterations of the pathway have been demonstrated concern 
the liver (i.e. hepatitis, cirrhosis, acute liver failure, 
hepatocellular carcinoma) (9,13), but its impairment in 
cardiovascular diseases (14,15), Alzheimer (16-18), 
psoriasis (19), rare diseases (i.e. Wilson disease) (20-22) 
and even hearing loss (12,23) has been also shown. It is 
not surprising that such a variety of pathological states 
concur with an anomalous function of the methionine 
cycle, given not only the large diversity of biological 
processes involving SAM, but also the connections of this 
pathway with additional key routes and its dependence on 
the nutrient status, as will be explained below. 
 
Figure 1. Mammalian methionine cycle and associated pathways. The scheme shows the main reactions involved in the methionine 
cycle, polyamine synthesis, folate cycle, trans-sulfuration and glutathione synthesis. A discontinuous blue line indicates the methionine 
salvage pathway. Enzymes and metabolites appear abbreviated as follows: MATs, methionine adenosyltransferases; PEMT, 
phosphatidylethanolamine N-methyltransferase; GNMT, glycine N-methyltransferase; GAMT, guanidinoacetate N-methyltransferase; 
MTases, methyltransferases; SAHH, S-adenosylhomocysteine hydrolase; ADK, adenosine kinase; ADA, adenosine deaminase; CBS, 
cystathionine β-synthase; CTH, cystathionase; GCS, γ-glutamylcysteine synthetase; GSS, glutathione synthetase; GSR, glutathione 
reductase; BHMT, betaine homocysteine methyltransferase; BHMT2, betaine homocysteine methyltransferase 2; MTR, methionine 
synthase; DHFR, dihydrofolate reductase; SHMT, serine hydroxymethyltransferase; MTHFR, methylene tetrahydrofolate reductase; 
AMD, S-adenosylmethionine decarboxylase; THF, tetrahydrofolate; DHF, dihydrofolate; MTHF, 5-methyl tetrahydrofolate; MeTHF, 
methylene tetrahydrofolate; MTA, methylthioadenosine; GSSG, glutathione oxidized form; GAA, guanidinoacetate; X, any methyl 
acceptor.
Methionine was discovered in 1923 by Mueller (24), and found to be essential for mammals in 1937, when 
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growth retardation was detected in rats fed methionine-free 
diets (25). Hence, this amino acid must be obtained from 
the diet, and after absorption, needs to be distributed to the 
whole organism, where requirements of each organ are not 
equal, as mentioned previously. Once into the cell the use 
of this amino acid is shared between protein synthesis and 
the methionine cycle, and part of the methionine consumed 
in these pathways can be recycled. Mammalian cells can 
recover part of the methionine used in the methionine 
cycle by homocysteine (Hcy) remethylation and also by 
the methionine salvage pathway, which has a minor role. 
Hcy remethylation requires additional methyl donors to 
synthesize methionine, being those mainly 5-methyl 
tetrahydrofolate (MTHF), but also betaine and S-
methylmethionine (vitamin U). These remethylation 
reactions are catalyzed by a vitamin B12-dependent 
methionine synthase (MTR; EC 2.1.1.13), betaine 
homocysteine methyltransferase (BHMT; EC 2.1.1.5) and 
BHMT2 (EC 2.1.1.10), respectively (26,27). The Hcy 
required for this purpose is generated as an intermediate in 
the trans-sulfuration pathway that converts methionine into 
cysteine, and in which SAM synthesis by MATs is the first 
step. Transmethylations then use the methyl donor 
rendering the methylated products together with 
demethylated SAM, named S-adenosylhomocysteine 
(SAH). Three methyltransferases in charged of the 
synthesis of small compounds are the main consumers of 
hepatic SAM. Namely, glycine N-methyltransferase 
(GNMT; EC 2.1.1.20), phosphatidylethanolamine N-
methyltransferase (PEMT; EC 2.1.1.17) and 
guanidinoacetate N-methyltransferase (GANMT; EC 
2.1.1.2) which synthesize sarcosine, phosphatidylcholine 
and creatine, respectively (13).  
The byproduct of transmethylations, SAH, is a potent 
inhibitor of most methyltransferases and its hydrolysis is 
carried out by SAH hydrolase (SAHH or AHCY; EC 
3.3.1.1) in the only reversible reaction of the methionine 
cycle, which renders adenosine and Hcy (9). Elimination 
of SAH is key in order to maintain an appropriate 
methylation level that depends on the SAM/SAH ratio, 
also known as the methylation index. Calculations carried 
out in several tissues have established that the optimal 
hepatic ratio is approximately 4, although this number is 
higher for other tissues such as the lung, where the 
preferred methylation index is around 9 (28). Preservation 
of these optimal SAM/SAH ratios depends on an efficient 
removal of Hcy, adenosine or both.  
Hcy levels depend on its catabolism through the 
remaining reactions of the trans-sulfuration pathway 
leading to cystathionine and cysteine, its elimination into 
the blood or, when methionine levels become low, its 
remethylation. The metabolic branch point represented by 
Hcy favors its use for cysteine synthesis through the 
consecutive activities of cystathione β-synthase (CBS; EC 
4.2.1.22) and cystathionase (CTH; EC 4.4.1.1). These two 
enzymes exhibit higher Km values for Hcy than 
remethylating proteins, are activated by high levels of 
SAM and require vitamin B6 (26,29,30). In parallel, 
adenosine can be utilized by adenosine deaminase (ADA; 
EC 3.5.4.4) or adenosine kinase (ADK; EC 2.7.1.20) to 
produce inosine or AMP, respectively (26). All these 
reactions connect the methionine cycle with multiple 
pathways in which regulators of the former are generated, 
hence creating a series of feedback loops whose 
complexity is not totally understood. Moreover, all the 
reactions described above do not show identical 
importance in every tissue, due to differences in gene 
expression patterns, and hence, on the enzymes or 
isoenzymes encountered in each cell type. 
Main players in the regulation of the hepatic 
methionine cycle are metabolites, from the same or related 
pathways, hormones and nutrients, some of their key 
effects being summarized below. Among the metabolites, 
SAM deserves a special consideration, since its role 
includes the activation or inhibition of several enzymes 
such as MATs, CBS and CTH, as well as the inhibition of 
BHMT expression (29,31,32). SAM further contributes to 
the inter-regulation between pathways by inhibiting 
methylene tetrahydrofolate reductase (MTHFR; EC 
1.5.1.20) of the folate cycle and regulating AMP kinase 
(AMPK; EC 2.7.11.31) phosphorylation (33,34). Nutrients 
such as vitamins of the B group, or their derivatives, also 
have a relevant role as cofactors or substrates for MTR, 
CBS and CTH, but also as inhibitors of GNMT in the form 
of MTHF (35-38). Moreover, methionine levels have been 
shown to regulate expression of MAT genes (39), and 
hormones seem to exert their role preferentially at the 
expression level, as occurs with glucocorticoids and MAT 
genes (40). Redox regulation is exerted by glutathione, and 
the ratio of its reduced (GSH) and oxidized (GSSG) forms 
(41-43), nitric oxide (44), hydroxyl radicals (45), NADP+ 
(46), copper (20,47), etc. on MATs and SAHH. 
Additionally, oxidative stress inhibits MTR and activates 
CBS through changes in the redox status of their cofactors, 
vitamin B12 and the heme group, respectively (48). 
3. METHIONINE ADENOSYLTRANSFERASES 
MATs are a family of enzymes highly conserved 
between Bacteria and Eukaryota. This conservation 
expands from the amino acid sequence to the protein 
structure, facts that allowed us to propose MATs as a good 
phylogenetic marker back in 2004 (49). Moreover, MATs 
from Archaea despite their low sequence conservation 
(∼18%) still preserve the amino acid residues involved in 
catalysis (50), suggesting that the mechanism for SAM 
synthesis has been maintained throughout evolution (5). 
This family of enzymes uses methionine and ATP as 
substrates in a reaction that requires Mg2+ and K+ ions and 
which takes place in two steps: 1) the transfer of the 
adenosyl moiety of ATP to the sulfur atom of methionine, 
generating SAM and triphosphate; and 2) the hydrolysis of 
the triphosphate originating pyrophosphate and inorganic 
phosphate and allowing SAM liberation from the active 
site (4,5).  
There are three MAT genes in mammals, named 
MAT1A, MAT2A and MAT2B, which encode two types of 
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catalytic subunits, MATα1 and MATα2, and the 
regulatory subunit MATβ, respectively (Figure 2). The 
high level of identity exhibited by MATα1 and MATα2 
(85% at the amino acid level), is not shared by MATβ, 
which is a non-related protein of the PFAM 04321 
oxidoreductase family (4,5). Four splicing forms of MATβ 
have been detected in hepatoma cells, from which the V1 
form is the protein encountered in normal tissues and 
which has been evaluated in most studies published to date 
(51).  
 
Figure 2. Methionine adenosyltransferase nomenclature. The scheme summarizes the nomenclature used in the field regarding genes, 
subunits, splicing forms (circled in green) and the oligomeric association of the subunits to render the isoenzymes found in the cytosol 
and the nucleus. 
MAT subunits associate into the three isoenzymes that 
have been detected in mammalian cells, named MAT I, 
MAT II and MAT III (Figure 2). Their characterization 
was carried out after their isolation from liver (MAT I and 
III) or kidney (MAT II) and found to be homo- or hetero-
oligomers (4). Precisely, MAT I and MAT III were 
identified as homo-tetramers and homo-dimers of MATα1 
subunits (52-54), respectively, whereas MAT II was 
classified as a hetero-oligomer of MATα2 and MATβ 
subunits (55,56). The affinity for methionine of the three 
isoenzymes expands the whole micromolar range 
(reviewed in (4,5)), some differences being encounter 
between laboratories, but mean data corresponding to the 
following values: 3 µM for MAT II; 30 µM for MATα2 
homo-oligomers; 100 µM for MAT I; and 1 mM for MAT 
III. In contrast, Vmax values showed the opposite trend, 
MAT II < MATα2 homo-oligomers < MAT I < MAT III. 
These kinetic parameters determine the capacity for SAM 
synthesis of each cell type, under normal or pathological 
conditions, according to the isoenzyme expressed and the 
level attained.  
The classical knowledge on MATs by the 90s can be 
summarized as follows (reviewed in (4)): i) normal liver 
was the solely tissue where MAT1A was expressed; ii) 
MAT2A was expressed in extrahepatic tissues, 
hepatopathologies and fetal liver; iii) MAT2B expression 
followed that of MAT2A, although at lower levels; iv) 
MAT isoenzymes were cytosolic proteins; v) MAT II was 
probably a heterotetramer (α22β2); v) binding of MATβ to 
MATα2 increased the affinity of the latter for methionine; 
vi) SAM inhibits MAT I and II isoenzymes, but is an 
activator of MAT III; vii) MAT III is activated by 
dimethylsulfoxide; viii) cysteine residues were found to be 
important for MAT I/III activity and in order to maintain 
the association state; and ix) SAM was transported from 
the cytoplasm to other subcellular compartments as 
required. During my posdoctoral in Mato's group in the 
early 90s we were able to provide additional evidences 
concerning MAT I and MAT III (reviewed in (4). Those 
included results obtained both in vitro and in vivo, the 
main achievements being as follows: i) further insights 
into the role of the cysteine residues; ii) the modulation of 
the activity by glutathione levels; iii) regulation of the 
isoenzyme activity by PKC phosphorylation; iv) the 
identification of the putative ATP binding site by 
photoaffinity labeling; v) the regulation by 
glucocorticoids; and vi) the differential expression pattern 
during liver development. Based on these accumulated 
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knowledge, several questions remained unanswered, being 
their response the objective of our group in the last 20 
years.  
4. OUR CONTRIBUTION TO UNDERSTAND 
MAMMALIAN METHIONINE 
ADENOSYLTRANSFERASES: FROM STRUCTURE 
TO NEW REGULATORY LEVELS 
The objective since we started our independent work 
by 1994 was to understand several aspects of MAT 
regulation that were poorly addressed, despite the intensive 
work of several groups since their discovery. Some of the 
limiting facts for the field at that time related to the 
difficult purification procedures to obtain the isoenzymes 
and the lack of good antibodies or structural information. 
Therefore, our initial work was focused on these aspects to 
develop better protocols and tools that allowed progress in 
the study of MATs, and which latter favored additional 
studies on animal models, as will be explained below. 
4.1. Association of α-subunits is required to obtain active 
MATs  
The first objective of our work was to understand the 
need for oligomerization of MAT α-subunits, and for this 
purpose we undertook the crystallization of rat MAT I and 
MAT III. Our initial attempts were based in the use of the 
rat liver purified proteins, but the heterogeneity of the 
sample precluded crystallization. Next, we tried to use the 
recombinant protein overexpressed in E. coli (53,54), and 
several important problems had to be faced: 1) the level of 
soluble protein was very low; 2) it was impossible to 
separate the recombinant protein from the bacterial MAT 
due to their high homology and identical chromatographic 
behavior; and 3) refolding of MAT I/III from the inclusion 
bodies required a protocol that had to be established. 
Nevertheless, we decided to pursuit the design of a specific 
refolding protocol (57), rendering large amounts of soluble 
protein, and that latter revealed its use for additional 
purposes. The success of this refolding protocol relied on 
the use of very low protein concentrations, the addition of 
Mg2+ to the buffers, the utilization of two refolding steps 
(fast and slow), and the maintenance of the 10 cysteines of 
rat MATα1 in a reduced state during the whole procedure 
(57). Characterization of the refolded protein showed that 
both MAT I and MAT III isoenzymes could be obtained, 
and their interconversion was possible just by 
concentration or dilution of the sample (57). Moreover, 
kinetic parameters and circular dichroism spectra of the 
refolded proteins were similar to those of the isoenzymes 
purified from rat liver (57,58). These facts, together with 
the large amount of refolded and purified MAT I/III 
obtained, led us to use these proteins in new crystallization 
attempts that were successful. 
 
Figure 3. Structural details of MATα1 and its dimer. A cartoon representation of the secondary elements found in rat MATα1 
monomers is shown in the upper left panel. An arrow indicates the position of the flexible loop of access to the active site in the 
completely folded subunit and the central domain is highlighted. The crystal structure of the MAT III appears on the right side of the 
figure, an arrow indicating the entrance to the active site located at the dimer interface. The lower part of the figure shows a magnification 
of the central domain, including the five cysteine residues located in this area (C35, C61, C57, C67, C105). The position of the 
intrasubunit disulfide (C35-C61) appears indicated by a circle. 
The crystal structure of rat MAT I was reported in 
2000, becoming the first mammalian structure solved for 
this family of proteins (59). MATα1 monomers showed a 
three-domain organization similar to that previously 
described for the E. coli counterpart (5) (Figure 3). The 
domains were formed by nonconsecutive stretches of the 
protein chain, each of them containing a β-sheet (59). The 
three sheets made up a large hydrophobic surface that 
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constituted the interaction interface between monomers in 
the dimer. The two active sites of each dimer located at 
this interface, opposite one to another, and their structure 
required residues of both subunits for catalysis (59,60). 
This organization therefore explained the need for 
association exhibited by MATα1 subunits, and the fact 
that dimers were the minimum active isoenzymes. 
Production of the crystals in the presence of substrates or 
certain analogues also allowed the identification of key 
residues for catalysis (59,60). Precisely, F251 was 
identified as key for methionine binding (59), whereas the 
role in ATP binding of a P-loop previously identified by 
photoaffinity labeling was confirmed (60,61). The next 
level of association involved the central domains of each 
monomer, which provided the few residues that allowed 
tetramerization, being the resulting interaction pattern 
much more limited then that previously described for E. 
coli MAT (62). How these interactions contribute to the 
changes in affinity and Vmax shown between MAT I and 
MAT III is still unknown and requires further 
investigation. 
4.2. Interconversion between MAT I and III isoenzymes is 
blocked by an intrasubunit disulfide bond 
The next question we addressed concerned the 
interconversion between MAT I and MAT III, and 
specifically what blocks this exchange, which is not 
observed in the liver purified isoenzymes. The sequence of 
MATα1 includes 10 cysteine residues and N-
ethylmaleimide modification of just one of them was 
responsible for a large loss of enzymatic activity. 
Moreover, modification of an additional sulfhydryl group 
led to inactive dimers (63). Analysis of mutants generated 
in all the cysteines confirmed the role of these residues in 
activity, and demonstrated that those comprised between 
C35 and C105 were involved in the control of the MAT 
III/I isoenzyme ratio (64). Latter on, C121 was identified 
as the target for inactivation by nitric oxide and 
hydroxylation (44,45,65), a role explained by its location 
in the loop of access to the active site (59,60). However, 
our initial studies using chemical modification also 
revealed that in the isoenzymes purified from rat liver two 
cysteine residues remained elusive, and that only after 
reduction they became accessible to N-ethylmaleimide 
modification (63,66). These data suggested the presence of 
a disulfide bond within MAT I and MAT III, which was 
identified as an intrasubunit bond involving C35 and C61 
in the isoenzymes isolated form rat liver (66) (Figure 3). 
The crystal structure of MAT I, obtained under reducing 
conditions, showed that these residues were well oriented 
and at a distance short enough to form such an intrasubunit 
bond (59). 
The role of the disulfide was further explored taking 
advantage of the available refolding procedure and 
cysteine mutants prepared on MATα1 (62). For this 
purpose, refolding was carried out under reduced (with 
DTT) or mild oxidative conditions (with GSH/GSSG 
mixtures). Analysis of the resulting refolded isoenzymes 
showed that interconversion between MAT I and MAT III 
could be produced only when the proteins were fully 
reduced (62). Moreover, mass spectrometry evaluation of 
the refolded proteins revealed that this interconversion was 
blocked by the presence of the C35-C61 disulfide bond in 
the isoenzymes resulting from refolding under mild 
oxidative conditions (62). Once more, the use of the 
available structural data allowed us to propose that the role 
of this intrasubunit disulfide relies in its ability to stabilize 
the β-sheet of the central domain involved in dimer-dimer 
interactions. Therefore, production of the disulfide at 
different steps during folding would result in stable 
tetramers or dimers. 
4.3. Unfolding of MAT I and MAT III takes place through 
an intermediate state 
Our two-step refolding protocol suggested the 
requirement of an intermediate state that must be well 
populated to obtain a correct association pattern of the 
MATα1 monomers into dimers, in order to avoid 
aggregation (57). Unfolding studies carried out on MAT 
III using urea as denaturant confirmed this hypothesis, and 
demonstrated a three-state mechanism that is reversible 
(58). The intermediate identified by gel filtration 
chromatography and sedimentation velocity was an 
inactive monomer with 70% of the native secondary 
structure, according to circular dichroism results. 
Moreover, the instability exhibited by the dimer in the 
presence of the denaturant was due to its dissociation, 
probably by weakening of the interface interactions 
between MATα1 monomers. In fact, we were able to 
calculate that approximately 50% of the global 
stabilization energy of MAT III was due to subunit 
association, whereas only 25% derived from the 
interactions stabilizing the intermediate state. MAT I 
unfolding was also studied taking advantage of the 
differences in fluorescence intensity exhibited by tetramers 
and dimers upon 8-anilinonaphtalene-1-sulfonic acid 
(ANS) binding. The results obtained suggested that around 
65% of the global free energy derives from dimer 
dissociation, thus supporting a lower stability for dimer-
dimer interactions (62). On the other hand, thermal 
denaturation of MAT I and MAT III was shown to be 
irreversible, regardless of the techniques used to follow the 
process. Only one transition was observed for both 
tetramer and dimer denaturation, hence suggesting that 
stability of MAT I is highly dependent on that of the dimer 
(67). Using two-dimensional infrared spectroscopy and the 
structural data it was possible to ascribe the earliest 
changes to the most exposed elements, α-helices and β-
turns. 
The high level of sequence and structural conservation 
among α-subunits suggested no large differences in 
folding pathways for MATα1 and MATα2 monomers, 
although association steps may diverge due to the 
incorporation of MATβ into MAT II hetero-oligomers. 
However, this initial hypothesis was demonstrated to be 
partially wrong when refolding of MATα2 was performed. 
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In fact, this subunit followed a similar pathway to produce 
MATα2 dimers, and only in a latter step association of 
MATβ takes place (46). Data regarding folding pathways 
in vivo remain very limited, although E. coli MAT was 
identified several years ago among the substrates for the 
chaperonin GroEL (68). 
All this information regarding folding and structure 
could be of help to understand the impact of the different 
MAT1A mutations detected in patients with isolated 
persistent hypermethioninemia, and in fact we performed 
this exercise in 2011 (69). Most of these patients are 
asymptomatic, although demyelination and other central 
nervous system manifestations have been described in 
several cases (70,71). The number of patients is still small, 
but newborn screenings in search for CBS defects are 
aiding in the identification of hypermethioninemias due to 
MAT1A mutations. Most mutations follow a recessive 
autosomal inheritance trait, although a dominant pattern 
has been described for the transition leading to the R264H 
protein mutant (72). The presence of early stop codons 
leading to shorter MATα1 subunits has been reported, as 
well as the possibility of longer chains due to mutations in 
the stop codon or splice-donor sites (70,71,73). Analysis of 
some of these mutant proteins has been carried out upon 
overexpression in E. coli and/or COS cells and their effects 
on activity evaluated. The early stop codons identified to 
date lead to proteins lacking from part (386X) or most 
(350X) of the C-terminal domain, to others in which even 
information for a complete domain is absent (92X and 
185X). Additional early stop codons (351X) result not 
only in the loss of half of the C-terminal domain, but also 
in a change of sequence that affects a portion of the central 
and the remaining C-terminal domains. In contrast, longer 
subunits resulting from the stop codon mutation (X396Y-
464X) present with the whole wild type sequence, and 
hence the information for the whole N- and central 
domains plus and extended C-terminal domain. Longer 
monomers due to splice-donor mutations on exon III, will 
result in proteins whose sequence is drastically altered, and 
hence, their folding and structure. If not eliminated by 
proteolysis, the shortest MATα1 subunits are expected to 
result in a complete change in the folding pattern, 
precluding association. However, those mutants in which 
the sequences for the N- and central domains remain 
intact, and even part of the C-terminal domain is 
preserved, may achieve an intermediate state that allows 
association (69).  
This is the case for mutations leading to MATα1 
subunits of approximately 350 residues, which were the 
first identified in patients with demyelination. In fact, 
Hazelwood et al. proposed that this type of subunits might 
associate with MATα2 monomers, leading to an inactive 
hetero-oligomer (74). Although plausible, given the high 
level of sequence identity between MATα1 and MATα2 
subunits, the availability of new structural data showed 
that there are small differences in the orientation of the 
monomers. Moreover, these mutants ∼350 residues long 
lack the C-terminal domain sequence involved the in 
monomer-monomer interface, including the β-sheet that 
participates in dimer association. These divergences 
together will impose a rearrangement to avoid exposure of 
amino acids that are hidden in the wild type MATα1, and 
hence reducing the probability of association with MATα2 
(69). Once again, additional experiments are needed for 
verification of the folding pathways followed by the 
mutants, their putative ability to hetero-oligomerize with 
wild type subunits, etc.  
4.4. Oxidative stress induced by copper accumulation 
impairs SAM synthesis in early stages of Wilson disease 
Several models of liver disease that induce oxidative 
stress by different mechanisms have been explored along 
the years regarding the alterations induced in SAM 
synthesis. Just to name some, carbon tetrachloride 
intoxications (75,76), treatments with buthionine 
sulfoximine (BSO) (42), Long Evans Cinnamon (LEC) 
rats (20-22), etc. all concur with a reduction in MAT 
activity and SAM levels. Now that the role of cysteines in 
MAT I and MAT III is known this is no longer a surprise, 
but since most of these models were explored earlier there 
was a need to revisit certain aspects. Among them, the case 
of the Wilson disease model provided by LEC rats 
remained underexplored, probably because of the rare 
condition of this pathology. The available data referred 
only to activity parameters and were determined in an 
advanced stage of the disease, where hepatitis was already 
present. Therefore, we decided to explore early 
pathological stages to get insight into the copper effects on 
SAM synthesis. For this purpose, we examined 9-week old 
LEC rats, which already presented with copper deposits in 
the liver, but no signs of hepatitis (20). 
Hepatic copper accumulation at this early step led to 
changes in expression that were unexpected for MAT 
genes (20). The Mat1a/Mat2a expression switch was 
already detected in LEC rats at this age, but Mat2b 
expression was dramatically reduced, hence following an 
opposite pattern to that classically described in liver 
disease. These effects on Mat2b expression were prevented 
by neocuproine, a chelator of Cu (I) (Figure 4). Reductions 
in SAH concentrations were larger than effects on SAM 
levels, probably due to the effects of copper on SAHH 
(47). Activity measurements carried out under conditions 
that allowed distinction between the three MAT 
isoenzymes indicated a decrease in MAT III activity, 
together with an increase in the combined activity of MAT 
I and MAT II. These effects on activity correlated with an 
enhancement in the MAT I content together with a 
reduction in that of MAT III, according to analytical gel 
filtration chromatography (AGFC) and dot blot detection 
of MATα1 (20).  
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Figure 4. Summary of the effects detected on S-adenosylmethionine synthesis in LEC rats. The different levels at which copper 
accumulation alters SAM synthesis are shown, as well as the modifications prevented by neocuproine administration. 
Further analyses of copper effects on MAT proteins 
were carried out in vitro taking advantage of the refolding 
protocol. These experiments showed effects on folding of 
MATα1 and MATα2, the presence of copper reducing the 
amount of soluble protein obtained, but having no effect in 
the association state attained. Moreover, addition of copper 
to correctly folded MATs had a direct effect on their 
activity (20). MATα2 dimers were more susceptible to 
inhibition than MAT I and MAT III under reducing 
conditions, whereas this pattern was opposite when 
reducing conditions were milder. This effect of copper on 
activity correlated with the generation of high-Mr 
aggregates, further supporting its role in the folding of 
MATs. In this case, the residues affected by oxidative 
stress remain unknown, and hence further studies should 
be carried out to understand the mechanism of copper 
effects on these proteins. 
4.5. The affinity between MAT II subunits is increased by 
NADP+ binding 
Several years latter crystal structures of human 
MATα2 homo-oligomers became available, monomers 
showing the same organization than MATα1, including 
three domains and a similar pattern for dimerization. 
Following this achievement structures of MATβ homo-
oligomers were solved and the presence of a Rossman-fold 
including NADP+ demonstrated (77). However, no 
explanation of the cofactor's role in the protein was 
provided. Therefore, we adapted the refolding protocol of 
the laboratory for human MATα2 production, and 
improved the methods for recombinant human MATβ 
production and purification (46). Using isothermal titration 
calorimetry we were able to determine the affinity 
parameters for NADP+ binding to MATβ, to demonstrate 
that the cofactor increases the affinity of MATβ for 
MATα2 subunits, and finally that MAT II is a hetero-
trimer composed by a MATα2 dimer and a single MATβ 
subunit (46).  
The structural data available also allowed the 
preparation of models for MAT II structure, the best 
approach suggesting that the interaction between the 
MATα2 dimer and MATβ not only involves the NADP+ 
binding site, but takes place close to the protein active site. 
The role of MATβ residues postulated to bind the cofactor 
was proven by site-directed mutagenesis, whereas 
additional mutants lacking part of the N-terminal (similar 
to the V2 splicing form) showed altered kinetic properties 
upon their association with MATα2 dimers (46). Several 
of our findings were confirmed by Murray et al. in 2014, 
including the stoichiometry between MATα2 and MATβ 
subunits (2:1), and the fact that the N-terminal end of 
MATβ regulates the activity of MAT II (46,78). However, 
their crystal structures of MAT II showed a different 
interaction surface for the subunits, suggesting a role for 
the C-terminal end of MATβ (in this case the V2 splicing 
form) and a tunnel at the interface of the MATα2 dimer 
(78). Again, and in spite of the effort already performed, 
more structural work is needed to clarify the disparities 
reported to date. 
4.6. MAT1A expression is not restricted to the liver 
Northern blots carried out on samples from animal 
models or human biopsies showed MAT1A expression in 
liver, together with a switch towards MAT2A expression in 
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liver disease (4,13,79,80). Moreover, the Mat1a-/- mouse 
developed severe hepatic pathology with age, most of 
these mice showing hepatocellular carcinoma (81). In 
contrast, most patients with hypermethioninemia due to 
mutations in this same gene either do not develop 
symptoms or those are neurological, including a few cases 
showing signs of demyelination by magnetic resonance 
imaging (MRI), as explained in a previous section 
(70,71,82). Therefore, in our opinion, there was a need to 
reexamine the tissue expression profile of MAT1A. Using 
real-time RT-PCR this analysis was performed in rat 
tissues, where expression was detected in almost all of 
those examined. Several expression levels were found: 1) 
high, shown in liver; 2) medium, exhibited by pancreas 
and lung; and 3) low, found in the rest of the tissues 
examined (83). This same pattern was further confirmed 
by western blot using an anti-MATα1 antibody developed 
in the last years in our laboratory using highly purified 
preparations of the protein (64,83). 
4.7. MATs are cytoplasmic and nuclear proteins 
Localization of MATs to the cytoplasm was a well-
established characteristic, based mainly in traditional 
subcellular fractionation studies and activity 
measurements. However, lack of good antibodies 
precluded confirmation of this statement for a long time. 
Again, using the new available antibody and 
immunohistochemistry we were able to detect MATα1 in 
both the cytoplasm and the nucleus, although nuclear 
localization was preferred in extrahepatic rat tissues (83). 
This discovery led to new questions regarding whether 
there was nuclear MAT activity and which were the 
isoenzymes present in that subcellular compartment. The 
answer to these points required the development of 
improved subcellular fractionation protocols and activity 
measurements that allowed not only detection of the small 
amount present in the nucleus, but also, and more 
important, to guarantee lack of contamination from the 
cytoplasm. In order to detect nuclear MAT activity, a 
highly concentrated nuclear extract from a whole rat liver 
was required, together with 4-fold increased levels of the 
radioactive tracer and longer reaction times. In parallel, 
LDH activity was measured to ensure complete 
elimination of the cytoplasm, and even more critical, the 
activity measurements (LDH and MAT) were carried out 
in the supernatant before nuclear protein extraction to 
ensure that the detected activity was specific of the nuclear 
compartment. Following this protocol, the specific MAT 
activity detected in the nucleus was approximately 250-
fold lower than in the cytoplasm (83). Regarding the 
nuclear isoenzymes, AGFC followed by dot-blot detection 
of MATα1 showed the protein as tetramers and 
monomers, the amount of MAT I being small (83). 
Therefore, the low nuclear MAT activity measured 
correlated with the presence of equivalent levels of MAT I 
in this compartment. 
4.8. Overlapping areas of the C-terminal end are involved 
in the subcellular distribution of MATα1 
SAM is a small compound that can be transported 
through the nuclear pore, but this structure limits the size 
of the proteins that can be translocated from one side to 
another of the nuclear membrane to near 50 kDa. This is 
almost the size of MAT α-subunits and is far below that of 
MAT I (180 kDa). Thus, understanding how MATα1 is 
distributed between the nucleus and the cytoplasm was our 
next objective. Many nuclear proteins present localization 
signals (NLSs) in their sequence (84), others contain 
conformational signals that mimic the classical NLSs (85), 
and in other cases binding to proteins including 
appropriate signals is preferred (piggy-back)(86). Among 
NLSs, the best-known or classical signals are mono- and 
bi-partite sequences rich in basic residues, for whose 
identification several bioinformatic tools are available. 
Using this software we were unable to identify a classical 
NLS in the rat MATα1 sequence, and hence the crystal 
structure was utilized to determine the existence of 
exposed clusters of basic residues that could mimic such 
NLSs. Our analysis revealed that the C-terminal of 
MATα1 is abundant in basic residues, and those exposed 
to the surface were selected for site-directed mutagenesis. 
The subcellular distribution of the mutants was analyzed 
by confocal microscopy and subcellular fractionation and 
the combined results allowed the identification of two 
overlapping areas in the monomer structure that were 
involved either in nuclear localization or cytoplasmic 
retention (83).  
Subcellular localization was independent of MAT 
activity, since an inactive mutant prepared on a residue 
involved in methionine binding (F251D) showed the same 
distribution than the wild type protein (83). Moreover, 
deletions at the C-terminal end, similar to those found in 
some patients showing demyelination (lacking 45 
residues), favored nuclear localization of the truncated 
MATα1 (83). Additionally, it was demonstrated that 
nuclear localization of MATα1 correlated with increased 
levels of the trimethylation of lysine 27 in histone 3 
(me3K27H3) (83), a well-known epigenetic repression 
mark. In contrast, other histone methylations examined 
were increased by overexpression of MATα1, 
independently of the subcellular distribution observed for 
the mutants. 
In 2011, MATα2 was also found in the nucleus during 
a proteomic analysis in search for protein-protein 
interactions of the MafK transcription factor (87). This 
study showed MATα2 acting as a transcriptional 
corepressor of MafK on the heme oxygenase 1 (HO-1) 
gene. Moreover, a role for MATβ and MAT activity in this 
repression system was described. This manuscript together 
with an Editorial in the same issue of Molecular Cell 
(87,88), supported the hypothesis, previously postulated by 
our group (83), suggesting that MATs are transported to 
nuclear locations where SAM synthesis is needed, whereas 
organelles such as the mitochondria use transport systems 
to obtain the compound from the cytoplasm. 
4.9. Nuclear accumulation of MATα1 is induced during 
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acute liver injury 
The results described in the previous section suggested 
that changes in MATα1 subcellular distribution might be 
related to disease development. In order to examine this 
possibility, we choose two rat models of acute liver injury 
that were previously used for partial characterization of 
alterations in cytosolic methionine metabolism (89-91). 
Precisely, D-galactosamine and paracetamol intoxications 
were known to induce reductions in MAT activity and 
SAM levels (89,90,92). These changes in the D-
galactosamine model were ascribed to an anomalous ratio 
of the MAT isoenzyme activities towards enhanced MAT 
III activity (89,90). We were able to reproduce these 
previous results in the cytosol, reductions in total MAT 
activity being more modest for paracetamol than for D-
galactosamine treatments (92,93). The mechanism of 
action of both drugs is quite different, D-galactosamine 
inducing depletion of the uridine pool (94), and thus 
highlighting the interest of analyzing putative expression 
changes in that model. After 48 hours of D-galactosamine 
treatment, changes in the mRNA levels of most genes in 
the methionine cycle were evident, namely: i) the 
Mat1a/Mat2a expression switch, followed by a more 
modest increase in Mat2b expression; ii) increased mRNA 
levels for Ahcy and Mtr; iii) enhanced expression of genes 
involved in glutathione synthesis; and iv) decreased 
expression of Gnmt and Bhmt (93). In general, genes 
considered "exclusively hepatic" showed lower expression. 
Additional analyses carried out showed that the 
changes induced by D-galactosamine in the cytosolic 
protein levels of MATα1, BHMT, SAHH and GNMT 
closely matched the alterations observed in their 
expression (93). Focusing specifically on MATα1, the 
protein levels were reduced by ∼50%, this decrease 
correlating with a severe alteration in the isoenzyme 
pattern according to AGFC profiles, where only a small 
amount of MAT III was detected (93)(Figure 5). 
Altogether these results followed the previously published 
pattern detected by activity measurements in the cytosol 
(89). Paracetamol intoxication produced a more modest 
decrease in cytosolic MATα1 protein levels together with 
a completely different pattern in the MAT isoenzyme 
profile by AGFC, where an increase in MAT I content was 
readily observed. Moreover, while the MAT III/I activity 
ratio increased in the cytosol of paracetamol treated livers, 
the opposite trend was followed by the protein ratio, thus 
suggesting a certain degree of inactivation of MAT I in 
these samples (93).  
Analysis of the nuclear effects of the treatments 
revealed accumulation of MATα1 in this compartment 
both by D-galactosamine and paracetamol intoxications 
(93). AGFC revealed increased levels of MAT I and a 
reduction in those of MATα1 monomers in nuclear 
fractions of D-galactosamine-treated livers, which 
correlated with the detection of enhanced nuclear MAT 
activity (Figure 5). In contrast, paracetamol induced a 
modest increase in nuclear MAT I levels, but no 
significant changes in activity were measured. However, in 
both models enhanced levels of the me3K27H3 repression 
mark were also detected. This lack of correlation between 
activity and the histone modification in paracetamol 
intoxication prompted us to evaluate nuclear SAM levels. 
However, the procedures needed to purify nuclear 
fractions precluded this measurement, given the exchange 
through the nuclear pore that takes place during the 
extensive washing steps required for isolation. These 
measurements will be only possible when appropriate 
imaging techniques become available. 
 
Figure 5. Summary of the effects detected in animal models of acute liver injury.  A schematic representation of the hepatic changes 
induced by acute D-galactosamine and paracetamol intoxications on glutathione levels, MATα1 subcellular localization and a repression 
signal in liver are depicted. The preventive effects of N-acetylcysteine (NAC) are also shown.  
4.10. Changes in the ratio between reduced and oxidized 
glutathione forms controls the nucleocytoplasmic 
distribution of MATα1. 
D-galactosamine and paracetamol are known to induce 
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redox stress and to reduce the GSH/GSSG ratio. Although 
the mechanism by which D-galactosamine exerts this 
effect seems rather indirect, this is not the case for 
paracetamol, whose detoxification requires GSH 
consumption, thus leading to altered GSH/GSSG ratios 
(94). As mentioned previously, my own work 
demonstrated in 1992 that MAT I and MAT III activities 
were modulated by the GSH/GSSG ratios and, at extreme 
concentrations of GSSG, even the association state was 
modified (41). Therefore, we decided to explore whether 
glutathione ratios exerted an additional role in the control 
of MATα1 subcellular distribution using a cellular system, 
which allowed multiple combinations of drugs. Available 
hepatic cell lines include hepatomas and iPS-hepatocytes 
with low or no MAT1A expression (79,95), and primary 
cultures of hepatocytes rapidly loose expression of this 
gene (40,96). Therefore, transfection was needed to 
explore MATα1 behavior in any of these systems, among 
which we chose the hepatoma H35 cell line for 
overexpression of tagged-MATα1 (93). D-galactosamine 
treatment in this system reproduced the changes detected 
in the rat model: i) reduction in the GSH/GSSG ratio; ii) 
decreased cytosolic levels of MATα1; iii) accumulation of 
MATα1 in the nucleus; and iv) increase of the me3K27H3 
signal. Agents that serve as sources of cysteine for 
glutathione synthesis, N-acetylcysteine (NAC) and SAM, 
were then combined with D-galactosamine treatment and 
their preventive effects evaluated (Figure 5). Among them, 
only NAC was effective in preventing all the changes 
induced by the drug (93). 
In this same cellular system the effects induced by 
paracetamol in the rat model were also reproduced, 
namely: i) GSH depletion with the concomitant decrease in 
the GSH/GSSG ratio; ii) nuclear accumulation of MATα1; 
and iii) increased levels of the me3K27H3 repression 
mark. However, in this case the combination of 
paracetamol with NAC only prevented effects on 
glutathione levels and MATα1 localization, whereas 
me3K27H3 levels remained elevated (93). Further 
confirmation of the role of GSH/GSSG ratio in the 
regulation of MATα1 subcellular distribution was 
obtained using BSO, a compound that inhibits glutathione 
synthesis. Again, BSO treatment reduced the GSH/GSSG 
ratio and nuclear MATα1 accumulation was induced in the 
cells, these effects being prevented by addition of 
glutathione ethyl ester (93). Differences between D-
galactosamine and paracetamol intoxications may relay not 
only in their effects on glutathione levels, but also in the 
ability of the paracetamol intermediate NAPQI for protein 
modification. Such modification involves again sulfhydryl 
groups, which are essential for MAT I and MAT III 
function, and hence additional studies are required to 
address this aspect. 
5. INTEGRATED FOR MATs AND FUTURE 
RESEARCH MODEL OF REDOX REGULATION  
Altogether the available data concerning redox 
regulation of MATs expand from expression to subcellular 
localization and were summarized in a hypothesis recently 
proposed by our group (97) (Figure 6). This new theory 
expands a previous proposal that we made back in 1992 
(98), by adding the accumulated knowledge obtained in 
these years. Since the purpose of this review is not to 
revisit these hypotheses, only a few data will be 
highlighted.  
Most efforts in the last decades have been concentrated 
in understanding the regulation of MAT expression, 
rendering information from transcription factors acting on 
the promoter (i.e. NFκB), the different gene methylation 
levels according to the liver state, stabilization of the 
mRNAs (i.e. AUF1 and HuR binding), etc. Our own work 
has been concentrated however in the proteins themselves, 
our results concerning from the structure (i.e. intrasubunit 
disulfide bond), to cofactor regulation (i.e. NADP+ 
binding) and, more recently, subcellular distribution of 
MATα1 and its relationship with disease. Briefly, the 
proposal indicates that the high SAM levels found in 
normal liver depend on: 1) low methylation levels of the 
MAT1A promoter allowing gene expression; 2) high 
MAT2A promoter methylation levels, together with 
decreased MAT2A mRNA stability by binding of meHuR; 
3) the normal ratios of GSH/GSSG preserving high MAT 
I/III activity in the cytosol and keeping MATα1 transport 
to the nucleus at low ratios, therefore maintaining adequate 
methylation levels of histones and DNA. In contrast, the 
low SAM levels found in damaged liver are due to the 
combination of: 1) an inversion of the promoter 
methylation levels, which become high for MAT1A and 
low for MAT2A promoters; 2) enhanced MAT2A and 
MAT2B transcription by the action of redox regulated 
transcription factors; 3) destabilization of MAT1A mRNA 
by AUF binding, together with stabilization of MAT2A 
transcripts by HuR binding; 4) increased oxidative stress 
leading to higher levels of NADP+ and reduced 
GSH/GSSG ratios, which together favor cytosolic MAT II 
accumulation, the low Vmax MAT; and 5) reduced 
GSH/GSSG ratios induce nuclear accumulation of 
MATα1 and MAT I providing higher nuclear SAM 
concentrations for epigenetic mechanisms.  
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Figure 6. Actualized version of the model proposed for redox regulation of MATs. The proposal includes the most significant data 
regarding normal liver (left) and damaged liver (right). Mean GSH/GSSG ratios in each situation are included, together with the changes 
detected in expression due to gene methylation or stabilization/destabilization of the mRNAs. Effects on the proteins include those 
derived from increased levels of the cofactors, altered association patterns and subcellular distribution rendering finally, high or low SAM 
levels in normal and damaged livers respectively.  
Redox regulation is probably the best-known 
mechanism controlling MAT function in disease states, but 
still questions regarding how copper exerts its effects on 
these enzymes remain unsolved. Additionally, the role of 
other actors in redox stress, such as NAD+/NADH or 
NADP+/NADPH ratios, should be explored in the whole 
methionine cycle and special attention should be paid on 
subcellular distribution. The number of enzymes of this 
pathway found in the nucleus is increasing (SAHH, 
GNMT, MATs) and their role in this compartment is 
underexplored. Possibilities such as moonlighting 
activities cannot be forgotten, neither the protein-protein 
interactions in which they might be involved. 
6. CONCLUSION  
In the last 20 years our group has developed protocols 
and tools for the study of MATs and the methionine cycle 
and, as a result of this effort, new data have been obtained 
both in vitro and in vivo. Altogether, these results have 
shown the existence of new levels of regulation for MATs 
that might be key for understanding their role in disease, 
but which could also be considered as putative targets for 
the development of new treatments. Moreover, some 
aspects uncovered during our work might be useful as 
biomarkers of disease, provided the adequate tissue 
samples and tools are available. In the near future, work in 
this field will require a larger effort on the solution of 
structures, the role of post-translational modifications, the 
identification of protein-protein interactions and 
development of imaging techniques able to evaluate 
subcellular levels of metabolites. Null mice models are 
valuable tools for the development of the field, but certain 
aspects concerning the proteins themselves cannot be 
analyzed in animals that lack their expression. Subcellular 
localization and its relationship with pathology lay within 
this category. 
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